Caitong International Asset Management’s TScan Therapeutics TCRX Stock Holding History

Caitong International Asset Management’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2	Buy	+2	New	+$2	﹤0.01%	2435

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Caitong International Asset Management's TCRX Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in TScan Therapeutics (TCRX) in Q1 2026: 2 shares worth $2. The stake represents ﹤0.01% of the portfolio and ranks #2435 among its holdings.

60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

Caitong International Asset Management held 2 shares of TScan Therapeutics worth $2 as of Q1 2026.
TScan Therapeutics was a new Caitong International Asset Management position in Q1 2026.
TScan Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2435 holding.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.